Product image of Gurdatol (Tolvaptan) supplied by GNH India

Gurdatol

Active Ingredient:
Tolvaptan
Origin:
EU

Gurdatol (Tolvaptan)

Gurdatol is the brand name for the oral medication Tolvaptan, a vasopressin V2 receptor antagonist supplied as tablets (strength not specified). It is a prescription‑only drug marketed in the European Union and classified under ATC code C03BX03. Tolvaptan selectively blocks V2 receptors, promoting free water excretion (aquaresis). The product is indicated for hyponatremia associated with SIADH and for managing autosomal dominant polycystic kidney disease in adults.

Manufacturer / TM Owner

Sandoz A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Gurdatol (tolvaptan) is prescribed for specific conditions where excess water retention or cyst growth is a concern.

  • Hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH).
  • Autosomal dominant polycystic kidney disease (ADPKD) to slow the increase in kidney volume.
  • Management of fluid overload in patients with heart failure when conventional diuretics are insufficient (off‑label, depending on local guidelines).
  • Adjunctive therapy in liver disease patients awaiting transplantation to control serum sodium (off‑label).

Side Effects

The safety profile of Gurdatol reflects its mechanism of promoting water excretion; side effects vary in frequency and severity.

Common

  • Increased thirst and dry mouth.
  • Polyuria (frequent urination).
  • Mild dizziness or fatigue.
  • Constipation.
  • Mild headache.

Serious

  • Severe dehydration.
  • Rapid rise in serum sodium (hypernatremia).
  • Liver injury indicated by elevated transaminases.
  • Allergic reactions such as rash or angioedema.
  • Significant hypotension.

Precautions & Warnings

Clinicians should evaluate several factors before initiating Gurdatol to minimize risks and ensure appropriate use.

  • Assess baseline serum sodium and renal function.
  • Monitor liver enzymes regularly during treatment.
  • Avoid use in patients with hypovolemia or anuria.
  • Use caution in elderly patients due to higher dehydration risk.
  • Ensure adequate fluid intake to prevent excessive water loss.
  • Review concomitant medications that affect sodium balance.
  • Contraindicated in patients with known hypersensitivity to Tolvaptan.

Avoid Interactions

Gurdatol can interact with other medicines that influence water balance, liver metabolism, or serum sodium levels.

Avoid

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole).
  • Concomitant use with other V2 receptor antagonists.
  • High‑dose NSAIDs that may impair renal function.

Use with caution

  • CYP3A4 inducers such as rifampin or carbamazepine.
  • Loop diuretics.
  • Lithium therapy.
  • Antihypertensives that could exacerbate hypotension.
  • Other agents that raise serum sodium levels.

Frequently Asked Questions

Gurdatol selectively antagonizes vasopressin V2 receptors in the renal collecting ducts, reducing water reabsorption and increasing free water excretion (aquaresis).

It is indicated for hyponatremia associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and for slowing cyst growth in autosomal dominant polycystic kidney disease (ADPKD).

By promoting free water loss, Gurdatol raises serum sodium concentration, helping correct hyponatremia in patients with SIADH.

Baseline and periodic assessment of serum sodium, renal function, and liver enzymes is recommended, along with monitoring for signs of dehydration.

Use in patients with pre‑existing liver disease requires caution and regular liver function testing, as Tolvaptan may cause hepatic injury.

Common adverse effects include increased thirst, polyuria, dry mouth, mild dizziness, constipation, and occasional headache.

Severe dehydration, rapid rise in serum sodium (hypernatremia), significant liver enzyme elevation, allergic reactions such as rash or angioedema, and marked hypotension should prompt urgent evaluation.

Patients are advised to maintain adequate fluid intake but do not need specific dietary sodium restrictions beyond those recommended for their underlying condition.

Strong CYP3A4 inhibitors can increase Tolvaptan plasma concentrations, raising the risk of adverse effects; such combinations should be avoided.

Elderly patients may be more susceptible to dehydration and hypotension; dose adjustment and close monitoring are recommended.

Combination with loop diuretics may be used under medical supervision, but patients should be monitored for excessive fluid loss and electrolyte disturbances.

If a dose is missed, patients should take it as soon as they remember unless it is near the time of the next scheduled dose; they should not double the dose and should consult their healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tolvaptan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT